

Tel.2726300/2726450/2726550

Fax: 2725272

Email: knhadmin@knh.or.ke

Ref: KNH/SCM/ADM.43 Date: 29<sup>th</sup> April, 2024

RE: ADDENDUM TO TENDER NO:

KNH/T/1A/2024-2026-SUPPLY AND DELIVERY OF PHARMACEUTICALS. KNH/T/1B/2024-2026-SUPPLY AND DELIVERY OF PHARMACEUTICALS. KNH/T/1C/2024-2026-SUPPLY AND DELIVERY OF PHARMACEUTICALS, KNH/T/1D/2024-2026-SUPPLY AND DELIVERY OF **PHARMACEUTICALS** KNH/T/1E/2024-2026-SUPPLY AND DELIVERY OF **PHARMACEUTICALS** 

## To: ALL BIDDERS

Pursuant to the Public Procurement and Asset Disposal Act section 75 and its attendant Regulations 2020 and Clause 7 on Amendment of Tender Documents, the Hospital wishes to make the following amendments/clarifications;

## 2. TECHNICAL EVALUATION

## 2B- Product evaluation

The Product Evaluation Criteria in the tender document has *COMPLETELY* been expunged and replaced with;

- a) Tenderers must submit samples that meet technical specifications and representing the products quoted for in all characteristics in original packaging, bearing the original label, package insert and product monograph and a summary of relevant product characteristics. The following will be evaluated at this stage where applicable:
  - Regulatory Approval (Includes annual retention certificates, Import licenses
    at the time of delivery of the products (for orphan medicines only), Or any
    other approvals from Pharmacy and Poisons Boards for import of the product.
  - 2. International non-proprietary name [INN] or British Approved Name [BAN]
  - 3. Acceptable compendia or monograph (BP, USP, French VIPAL, International Pharmacopoeia, Innovator products) where applicable

- 4. Name & address of manufacturer
- 5. Pharmaceutical formulation, strength of active ingredients & unit of issue
- 6. Batch number, manufacture & expiry dates
- 7. Storage requirements
- 8. Direction for use including route of administration, instructions for reconstitution, dilution & stability information in English
- 9. Integrity of external & internal packages, labels & closures
- 10. Dispensing measures, accessories & ease of use
- 11. Consistency & uniformity of formulation & colour
- 12. Marketing authorization for medicines with import licenses, that can be used as marketing authorization in our market.
- 13. No documented poor-quality report

## Samples must:

- i. Not be expired within the tender validity period
- ii. Be the actual presentation of the product to be supplied.
- iii. Have a plain label bearing the tender number and product code as indicated in the price schedule.

Original information literature, complete and in English language, must accompany each product

Bidders will be required to submit samples during the tender evaluation period after the preliminary stage. The Hospital will give communication on sample submission.

Tender Opening and Closing date *REMAINS* as earlier communicated ie 8<sup>th</sup> May, 2024.

Rose M. Njoroge, OGW

FOR: CHIEF EXECUTIVE OFFICER